Emmaus Life Sciences (Formerly Known As Emmaus Medical, Inc.)

109 articles with Emmaus Life Sciences (Formerly Known As Emmaus Medical, Inc.)

• Emmaus Life Sciences Announces Submission of Marketing Authorization Application to Swissmedic Ideogen, A.G. to Manage Early Access Program

  6/15/2021

   Emmaus Life Sciences, Inc. (OTC: EMMA), announced today it has received confirmation from the Swiss Agency for Therapeutic Products (Swissmedic) of Emmaus' application for Marketing Authorization (MA) for Endari® in Switzerland.

• Emmaus Life Sciences Announces Submission of Marketing Authorization Application for Endari® to the Saudi Food & Drug Authority

  5/26/2021

  Emmaus Life Sciences, Inc. (OTC: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, announced today that  its application for Marketing Authorization (MA) for Endari® in the Kingdom of Saudi Arabia has been accepted by the Saudi Food and Drug Authority (SFDA)

• Emmaus Life Sciences Reports Annual Financial Results for 2020 and Provides Updated Business Review

  5/4/2021

  Emmaus Life Sciences, Inc. (OTC: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, announced today its financial results for the year ended December 31, 2020 as reported in its Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC").   

• Emmaus Life Sciences Provides Form 10-K Filing Update

  4/15/2021

  Emmaus Life Sciences, Inc. (OTC: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, announced today that its Audit Committee will meet the week of April 19 to review and approve the filing of the company's 2020 Annual Report on Form 10-K and related earnings release.

• Emmaus Life Sciences Announces Collaboration with Kainos Medicine for Preclinical Development of IRAK4 Inhibitor as Potential Anti-Cancer Drug

  3/2/2021

   Emmaus Life Sciences, Inc. (OTC: EMMA) , a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, announced today that it has entered into an agreement with Kainos Medicine, Inc. ("Kainos") to lead the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug

• Emmaus Life Sciences Reports Increase in Sales Volume in 2020

  1/27/2021

  Emmaus Life Sciences, Inc. (OTC: EMMA), a leader in the treatment of sickle cell disease, reports that it sold 25,947 boxes of Endari® in 2020 compared to 24,797 boxes in 2019, an increase of 5%.

• Michigan Revises Prior Authorization Criteria for Endari®

  12/10/2020

  Emmaus Life Sciences, Inc., a leader in the treatment of sickle cell disease, announced that it was notified by the Michigan Department of Health and Human Services that the prior authorization criteria for Endari® was revised after being reviewed by Michigan's Medicaid Health Plan Common Formulary Workgroup.

• Emmaus Life Sciences Launches Endari® Support Program

  12/8/2020

  Emmaus Life Sciences, Inc. (OTC: EMMA) , a leader in the treatment of sickle cell disease, announced today the launch of the Endari® Support Program. The Program is intended to provide patients who are unable to afford Endari® access to the medication for minimal or no-cost. Emmaus has partnered with Lash Group's TheraCom Sp

• Endari® Granted Orphan Drug Status in Switzerland

  12/3/2020

   Emmaus Life Sciences, Inc. (OTC: EMMA), a leader in the treatment of sickle cell disease, announced today that the Swiss Agency for Therapeutic Products (Swissmedic) has granted orphan drug status to Endari®. Orphan drug status (ODS) is available to medicinal products that treat conditions affecting no more than 5 out of 10,000

• Emmaus Life Sciences Submits Temporary License Application in Bahrain for Endari®

  11/10/2020

   Emmaus Life Sciences, Inc. (OTC: EMMA), a leader in the treatment of sickle cell disease, announced today that it has submitted a temporary license application for Endari ® to the National Health Regulatory Authority in the Kingdom of Bahrain . Approval of the temporary application takes one to two months and is a prerequisi

• FDA Approves Updated Label for Endari®

  11/3/2020

   Emmaus Life Sciences, Inc. (OTC: EMMA) , a leader in sickle cell disease treatment, announced today revised prescribing information for Endari® to better inform healthcare professionals and sickle cell disease patients. Based on approval from the FDA, the updated label includes a statement that the clinical benefit of Endari ®

• Emmaus Life Sciences Announces the Sale of its Telcon RF Pharmaceutical Inc. Shares

  10/14/2020

   Emmaus Life Sciences, Inc. (OTC: EMMA), a leader in sickle cell disease treatment, announced today that it has sold all remaining common shares of South Korea -based Telcon RF Pharmaceutical Inc. (KOSDAQ: 200230) in accordance with the Telcon agreement reported by Emmaus in its Current Report on Form 8-K fi

• Emmaus Life Sciences Announces Informational Stockholders Meeting--Meeting Will be Open to the Public--

  9/1/2020

  Emmaus Life Sciences, Inc. (OTCPK: EMMA), a leader in sickle cell disease  treatment, announced today that it will hold an informational meeting of stockholders at which management will provide an update on recent sales activities and other business and operations, as well as the status of the filing of Emmaus’ Annual Report on Form 10-K for the year ended December 31, 2019

• UPDATE - Emmaus Life Sciences Announces Submission of Marketing Authorization Application to the Saudi Food and Drug Authority

  8/18/2020

  Emmaus Life Sciences, Inc. (OTCPK: EMMA) , a leader in sickle cell disease treatment, announced today the submission of an application to the Saudi Food and Drug Authority (SFDA) for Marketing Authorization (MA) for Endari ® in the Kingdom of Saudi Arabia. This follows Emmaus’ announcement that the SFDA had granted Endari ® a priority review designation as part of its program to expedite the review of drugs that are expected to have a sign

• Emmaus Life Sciences Announces Submission of Marketing Authorization Application to the Saudi Food and Drug Authority

  8/18/2020

  Emmaus Life Sciences, Inc. (OTCPK: EMMA) , a leader in sickle cell disease treatment, announced today the submission of an application to the Saudi Food and Drug Authority (SFDA) for Marketing Authorization (MA) for Endari ® in the Kingdom of Saudi Arabia. This follows Emmaus’ announcement that the SFDA had granted Endari ® a priority review designation as part of its program to expedite the review of drugs that are expected to have a sign

• Emmaus Life Sciences Reports Additional Positive Preliminary Results in Diverticulosis Pilot Trial

  8/5/2020

  Interim Analysis Indicates Decreased Number of Diverticula and Healthy Tissue

• Emmaus Life Sciences Provides Additional Operational and OTC Markets Updates

  7/31/2020

  Emmaus Life Sciences, Inc. (OTCQB: EMMA) , a leader in sickle cell disease treatment, provided today additional operational updates for the year ended December 31, 2019 as well as operational updates for the quarters ended March 31 and June 30, 2020 in advance of the filing of its Annual Report on Form 10-K for 2019 and Quarterly Reports on Form 10-Q for the first and second quarters of 2020. “We continue to work with our predecessor audito

• Emmaus Life Sciences Accelerates Middle East and North Africa (MENA) Growth Strategy with Opening of its Dubai Office

  7/23/2020

  Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, announced today the opening of its regional office in Dubai.

• Emmaus Life Sciences Announces Engagement of Partner International to Lead Out-Licensing of Endari® for Diverticulosis

  7/16/2020

  Emmaus Life Sciences, Inc. (OTCQB: EMMA) , a leader in sickle cell disease   treatment, is pleased to announce that it has engaged Partner International to lead the out-licensing activity for Emmaus’ prescription grade L-glutamine (PGLG) oral powder for use in the treatment of diverticulosis.  This is the same active pharmaceutical ingredient found in Endari®, which is approved by the FDA and the Israeli Ministry of Health to reduce acute co

• Emmaus Life Sciences to Restate Previously Issued Financial Statements

  7/8/2020

  Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, today announced it will be restating its previously issued audited consolidated financial statements for the twelve months ended December 31, 2018 and unaudited quarterly statements for the three and nine months ended September 30, 2019.